Conditions: Neoplasms, Breast
Keywords: GW572016 Breast Cancer RECIST Inflammatory Breast Cancer Pazopanib ErbB2 Cutaneous Disease Tykerb Inflammatory Skin Her2 Lapatinib GW786034
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 163
Healthy volunteers: no

Brief summary:
The double blind part of the study is being conducted to compare the efficacy and safety of pazopanib in combination with lapatinib with that of lapatinib alone in subjects with inflammatory breast cancer whose tumors overexpress the ErbB2 protein. There is also an Open-label pazopanib arm to this study designed to test whether pazopanib given alone and lapatinib given alone would be safe and effective to treat patients with inflammatory breast cancer.

Detailed description:

Arms:
arm 1: Lapatinib arm 2: Pazopanib monotherapy (open label) arm 3: Lapatinib+ pazopanib

Interventions: intervention 1: lapatinib intervention 2: Pazopanib
Intervention descriptions: intervention 1: Oral administration intervention 2: Oral administration

Protocol document: